Pagoda Clinical Trial
Patients with Diabetic Macular Edema (closed for recruitment)
The purpose of this study is to investigate the effects and safety of the Port Delivery System (PDS) in patients with Diabetic Macular Edema (DME). The PDS is an investigational drug delivery technology that allows physicians to continuously treat the eye with medication rather than frequent intravitreal injections.
Diabetic macular edema (DME) is the term used for swelling in the small central part of the retina used for sharp, straight ahead vision due to diabetes. The retina is a thin layer of tissue that lines the back of your eye. It is nourished by blood vessels that become affected by diabetes.
All participants will receive either Ranibizumab injections or the investigational Port Delivery System with Ranibizumab. No one will receive a placebo.